,	Application No.	Applicant(s)	
Notice of Allowability			
	09/903,248 Examiner	WANDS ET AL. Art Unit	
	Karen A Canella	1642	
The MAILING DATE of this communication appear All claims being allowable, PROSECUTION ON THE MERITS IS (herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RICO of the Office or upon petition by the applicant. See 37 CFR 1.313	OR REMAINS) CLOSED in the or other appropriate communi GHTS. This application is sub	is application. If not included cation will be mailed in due course	e. THIS e initiative
1. This communication is responsive to			
2. The allowed claim(s) is/are 29, 31, 34,-36, 39-42, 45-47, 51 respectively.	, 52, 54, 56 and 59-62, renum	bered as 1, 2, 16-18, 7-15, 19, 20	and 3-6,
3. The drawings filed on are accepted by the Examiner.			
4. ☐ Acknowledgment is made of a claim for foreign priority und a) ☐ All b) ☐ Some* c) ☐ None of the: 1. ☐ Certified copies of the priority documents have		f).	
2. ☐ Certified copies of the priority documents have		No	i
3. Copies of the certified copies of the priority doc	* *		om the
International Bureau (PCT Rule 17.2(a)).			
* Certified copies not received:			
Applicant has THREE MONTHS FROM THE "MAILING DATE" on noted below. Failure to timely comply will result in ABANDONMETHIS THREE-MONTH PERIOD IS NOT EXTENDABLE.	of this communication to file a ENT of this application.	reply complying with the requirem	ents
5. A SUBSTITUTE OATH OR DECLARATION must be submit INFORMAL PATENT APPLICATION (PTO-152) which gives	ted. Note the attached EXAM s reason(s) why the oath or de	NER'S AMENDMENT or NOTICE claration is deficient.	OF
6. CORRECTED DRAWINGS (as "replacement sheets") must	be submitted.		
(a) $oxed{\boxtimes}$ including changes required by the Notice of Draftsperso	on's Patent Drawing Review (PTO-948) attached	
1) ☑ hereto or 2) ☐ to Paper No./Mail Date			
(b) ☐ including changes required by the attached Examiner's Paper No./Mail Date	Amendment / Comment or in	the Office action of	
ldentifying indicia such as the application number (see 37 CFR 1.8 each sheet. Replacement sheet(s) should be labeled as such in the	4(c)) should be written on the c e header according to 37 CFR 1	rawings in the front (not the back) (of
7. DEPOSIT OF and/or INFORMATION about the depos attached Examiner's comment regarding REQUIREMENT F	it of BIOLOGICAL MATER OR THE DEPOSIT OF BIOLO	IAL must be submitted. Note the DGICAL MATERIAL.	е
Attack magnetics)			
Attachment(s) 1. Notice of References Cited (PTO-892)	5. Notice of Infor	nal Patent Application (PTO-152)	
2. ☑ Notice of Draftperson's Patent Drawing Review (PTO-948)	6. Interview Sum	• • • • • • • • • • • • • • • • • • • •	
Information Disclosure Statements (PTO-1449 or PTO/SB/08 Paper No./Mail Date	Paper No./Ma	il Date	
4. ☐ Examiner's Comment Regarding Requirement for Deposit	8. ☐ Examiner's Sta	tement of Reasons for Allowance	
of Biological Material	9. Other		İ
			1

Application/Control Number: 09/903,248

Art Unit: 1642

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Ingrid Beattie on April 1, 2004.

The application has been amended as follows:

Claims 33 and 43 have been canceled.

Claim 29 has been substituted with the following:

29. A monoclonal antibody that binds to an epitope within the catalytic domain of HAAH, wherein said antibody binds to residues 650-700 of SEQ ID NO:2.

Claim 34 has been substituted with the following:

34. A kit for the diagnosis of a tumor in a mammal comprising a monoclonal antibody that binds to an epitope with the catalytic domain of HAAH, wherein said antibody binds to residues 650-700 of SEQ ID NO:2.

Claim 39 has been substituted with the following:

Application/Control Number: 09/903,248

Art Unit: 1642

39. A monoclonal antibody or a fragment thereof, wherein said antibody or fragment thereof binds to an epitope of SEQ ID NO:2, and wherein said antibody is produced by hybridoma ATCC designation PTA 3386.

Page 3

Claim 51 has been substituted with the following:

51. The composition of claim 45, wherein said cytotoxic agent is ricin.

Claim 52 has been substituted with the following:

52. The composition of claim 45, wherein said cytotoxic agent is diphtheria toxin.

Claim 59 has been added:

59. A monoclonal antibody 5C7 produced by hybridoma ATCC designation PTA 3383.

Claim 60 has been added:

60. A monoclonal antibody 19B produced by hybridoma ATCC designation 3384.

Claim 61 has been added:

61. A monoclonal antibody 86A produced by hybridoma ATCC designation 3385.

Claim 62 has been added:

62. A monoclonal antibody FB501 produced by hybridoma ATCC designation 3386.

Art Unit: 1642

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Karen A Canella whose telephone number is (571)272-0828. The examiner can normally be reached on 10 a.m. to 9 p.m. M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler can be reached on (571)272-0871. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Karen A. Canella, Ph.D. Art Unit 1642

Narm a. Gamella ARENA. CANELLA PH.D